Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study

This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Recruitment

Summary

Participation Requirements

Description

Tracking Information